7-(d-(alpha-amino-alpha-phenyl-,2-thienyl-and 3-thienylacetamido)-3-(s-(1-methyl-1,2,3-triazol-4-yl)carbonyl)thiomethyl-3-cephem-4-carboxylic acids

ABSTRACT

7-(D - (A-AMINO-A-PHENYL-, 2-THIENYL- AND 3-THIENYLACETAMIDO))-3-(S-(1-METHYL - 1,2,3 - TRIAZOL - 4-YL)CARBONYL)-THIOMETHYL-3-CEPHEM-4-CARBOXYLIC ACIDS AND THEIR NONTOXIC, PHARMACEUTICALLY ACCEPTABLE SALTS ARE VALUABLES AS ANTIBACTERIAL AGENTS, AS NUTRITIONAL SUPPLEMENTS IN ANIMAL FEEDS, AS AGENTS FOR THE TREATMENT OF MASTITIS IN CATTLE AND AS THEREPEUTIC AGENTS IN POULTRY AND ANIMALS, INCLUDING MAN, AND ARE ESPECIALLY USEFUL IN THE TREATMENT, PARTICULARLY BY ORAL ADMINISTRATION, OF INFECTIOUS DISEASES CAUSED BY MANY GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA. ALSO INCLUDED IN THIS INVENTION ARE THE CORRESPONDING PIVALOYOXYMETHL, ACETOXYMETHYL, METHOXYMETHYL, ACETONYL AND PHENACYL ESTERS OF SUCH ACIDS AND THEIR NONTOXIC, PHARMACEUTICALLY ACCEPTABLE ACID ADDITIONAL SALTS.

United States Patent 3,780,032 7-[D-(a-AMINO-e-PHENYL, 2 TTHENYL- AND 3- 'I'HIENYLACETAMIDO] 3-[S-(1-METHYL 1,2,3- TRIAZOL 4 YL)CARBONYL]THIOMETHYL-3- CEPHEM-4-CARBOXYLIC ACIDS John Michael Essery and Lee Cannon Cheney, Fayetteville, N.Y., assignors to Bristol-Myers Company, New York, N.Y. No Drawing. Filed Feb. 25, 1972, Ser. No. 229,548 Int. Cl. C07d 99/24 U.S. Cl. 260-243 C 44 Claims ABSTRACT OF THE DISCLOSURE 7 [D (oz-amino-a-phenyb, Z-thienyland 3-thienylacetamido)]-3-[S-(1-methyl 1,2,3 triazol 4-yl)carbonyl]-thiomethyl-3-cephem-4-carboxylic acids and their nontoxic, pharmaceutically acceptable salts are valuable as antibacterial agents, as nutritional supplements in animal feeds, as agents for the treatment of mastitis in cattle and as therapeutic agents in poultry and animals, including man, and are especially useful in the treatment, particularly by oral administration, of infectious diseases caused by many Gram-positive and Gram-negative bacteria. Also included in this invention are the corresponding pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl and phenacyl esters of such acids and their nontoxic, pharmaceutically acceptable acid addition salts.

BACKGROUND OF THE INVENTION (1) Field of the invention The cephalosporins of the present invention possess the usual attributes of such compounds and are particularly useful in the treatment of bacterial infections by oral administration.

(2) Description of the prior art (A) Cephalosporins in general.Cephalothin and cephaloridine are well-known antibacterial agents; see US. Pats. 3,218,318; 3,449,338 and 3,498,979. The literature also contains considerable data on the activity of cephaloglycin and cephalexin; see US. Pats. 3,303,193, 3,507,861 and 3,560,489 and Great Britain 985,747 and 1,054,806. Newer cephalosporins include cefazolin and cephapirin; see US. Pat. 3,516,997 and also Netherlands 68/05179 (Farmdoc 34,328) and South Africa 68/4513] and US. Pat 3,422,100.

The literature on cephalosporins has been reviewed by E. P. Abraham, Quart, Rev. (London) 21, 231 (1967) by E. Van Heyningern, Advan. Drug Res., 4, 1-70 (1967) and briefly in Annual Reports in Medicinal Chemistry, Academic Press, Inc., 111 Fifth Avenue, New York, N.Y., 10003, by L. C. Cheney on pages 96 and 97 (1967) and by K. Gerzon and R. B. Morin on pages 90-93 (1968) and by Gerzon on pages 79-80 (1969) and by L. H. Conover on pages 101-102 1970). New cephalosporins are frequently reported at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy as illustrated by Sassiver et al., Antimicrobial Agents and Chemotherapy- 1968, American Society for Microbiology, Bethesda, Md., pages 101-114 (1969) and by Nishida et al., ibid, 236- 243 (1970). Two excellent reviews are The Cephalosporins Microbiological, Chemical and Pharmacological Properties and Use in Chemotherapy of Infection L. Weinstein and K. Kaplan, Annals of Internal Medicine, 72, 729-739 (1970) and Structure Activity Relationships Among Semisynthetic Cephalosporins, M. L. Sassiver and A. Lewis, Advances in Applied Microbiology, edited by D. Perlman, 13, 163-236 1970), Academic Press, New York. Two more recent reviews are fl-Lactam Antibiotics: Their Physicochcmical Properties and Biological Activities in Relation to Structure, J. P. Hou and I. W. Poole, I. Pharmaceutical Sciences, 60(4), 503-532 (April, 1971) and Chemistry of Cephalosporin Antibiotics, R. B. Morin and B. '6. Jackson, Fortschr. Chem. Org. Naturst, 28, 343-403 (1970) which includes a section on nucleophilic displacement of the acetate group at pages 370-373.

The preparation of various 7-[a-amino-arylacetamido]- oephalosporanic' acids and the corresponding desacetoxy compounds in which aryl represents unsubstituted or substituted phenyl or 2- or 3-thenyl is described, for example, in British specifications 985,747, 1,017,624, 1,054,- 806 and 1,123,333, in Belgium Pat. 696,026- (Farmdoc No. 29,494), in US. Pats. 3,311,621, 3,352,858, 3,489,750, 3,489,751, 3.489,752, 3,518,260 and 3,575,969, in Japanese Pat. 1687 1/ 66 (Farmdoc 23,231), by Spencer et al., J. Med. Chem., 9(5), 746-750 (1966), by Ryan et al., J. Med. Chem., 12, 310-313 (1969) and by Kurita et al., I. Antibiotics (Tokyo) (A) 19, 243-249 (1966) and see also US. Pat. 3,485,819. British specification 1,073,530

includes a disclosure of the preparation of such compounds by acylation of sililyated 7-ACA.

Netherlands Pats. 68/ 11676 (Farmdoc 36,349) and 68/ 12382 (Farmdoc 36,496) and US. Pats. 3,489,750 and 3,489,751 disclose ring-substiuted cephaloglycins.

(B) 3 thiomethylcephalosporins.Various cephalosporins, including cephalosporin C on occasion but not cephaloglycin, have been reacted with nucleophilic, aromatic mercaptans to produce compounds having the structure In US. Patent 3,278,531 Ar is phenyl or certain substituted phenyls or certain aromatic heterocyclic rings named, for example, in column 5. Similar nucleophiles, e.g. Z-mercaptopyrimidines, are disclosed in US. 3,2-61,- 832 and Great Britain 1,101,422 and US. 3,479,350 and US. 3,502,665, all issued to Glaxo. A parallel disclosure is found in Great Britain 1,109,525 to Ciba, e.g. in definition h for R Additional nucleophiles of this type were disclosed by Fujisawa in Belgium 714,518 (Farmdoc 35,307; Netherlands 68/06129 and South Africa 2695/68), in Canada 818,501 (Farmdoc 38,845), in Great Britain 1,187,323 (Farmdoc 31,936; Netherlands 67/ 14888), in US. 3,530,123 and in US. 3,516,997 (Farmd-oc 34,328; Netherlands 68/05179) which includes the compound named cefazolin, which has a tetrazolylacetyl sidechain on the 7-amino group and a S-methylthiadiazolylthiomethyl group at the 3-position and is described at some length in the scientific literature, e.g. in Antimicrobial Agents and Chemotherapy-1969, American Society for Microbiology, Bethesda, Md., at pages 236-243 and in I. Antibiotics (Japan) 23(3), 131-148 (1970);

Replacement of the 3-acetoxy group of a cephalosporin by various heterocyclic thiols has been disclosed in US. 3,563,983 and in Netherlands 70/05519 (Farmdoc 80,- 188RR) where the sidechains were, for example, 7-vzaminophenylacetamido and typical heterocyclic thiols were 2-methyl-1,3,4-thiadiazole-5-thiol and 1-methyl-1,2, 3,4-tetrazole-5-thiol.

Various cephalosporins having the structure in which acyl represents various sidechains including aaminophenylacetyl have been described in some of the above and by Glaxo in Belgium 734,532 (Farmdoc 41,619) and in Belgium 734,533 (Farmdoc 41,620) and by Lilly in Belgium 743,754 (Farmdoc 41,150R).

Cephalosporins having the structure S 6 Acyl-NH-CH-O CH2 -N CHr-X where X includes S N- II II -S-C- and S-C- are disclosed in many patents including some of the above and in US. 3,239,516, 3,239,515, 3,243,435, 3,258,461, 3,431,259, 3,446,803, 3,278,531, 3,261,832 and 3,573,298.

Related publications in the scientific literature include J. Med. Chem. 8, 174--181 (1965) and J. Chem. Soc. (London) 1595-41605 (19 65), 5015-5031 (1965) and 1959-1963 (1967).

(C) 3 acylthiomethylcephalosporins.The following publications and patents disclose certain additional 7- ACA derivatives containing a 3-acylthi0methyl moiety (in which phenyl is abbreviated as Ph):

(1) G. F. H. Green, J. E. Page, and S. E. Staniforth, J. Chem. Soc., 1595-605 (1965 This reference gives the proton magnetic resonance spectra of the 3-benzoylthiomethyl derivative of cephalothin.

Cocker et al., J. Chem. Soc., 114241151 (1966) adds thiopieolinyl and references Belgium 650,444.

(2) J. D. Cocker et al., J. Chem. Soc., 50l531 (1965) discloses compounds having the structure S RCONH- wherein R has the following meanings:

(3) Glaxos US. 3,261,832 discloses compounds having the structure wherein Y has, for example, the following meanings:

4 Equivalents are Netherlands 64/08066 (Farmdoc 15534 and Great Britain 1,101,424.

(4) Glaxos Netherlands 65/06818 (Farmdoc 19,306) discloses the reaction An equivalent is US. 3,502,665. (5) Glaxos Netherlands 64/ 11521 [Chem. Abstr., 63: 13281d (1965 discloses the reaction thioacid JOOH Equivalents are Great Britain 1,101,422 and Canada 796,747 (Farmdoc 17362).

(6) Cibas US. 3,555,017 discloses compounds having the structure OOH R and R =halogen.

As usual in Cibas patents directed primarily to novel sidechains at the 7-position, the R group above is defined broadly as the residue of a carboxylic acid and may be illustrated by phenyl, as the residue of thiobenzoic acid. Equivalents are Belgium 708,241 (Farmdoc 33,276), Great Britain 1,211,747 and French 1,575,554.

(7) Cibas British 1,211,718 discloses compounds having the structure R as in 6 above Equivalents are Belgium 708,311 (Farmdoc 33,277) and US. 3,557,104.

(8) Cibas Belgium 751,526 (Farmdoc 90,178R) discloses compounds having the structure s mcmoo-Nn OOH R an in 6 above.

An equivalent is Netherlands 70/ 08237. (9) Cibas South Africa 69/8436 discloses compounds having the structure O OH R as in 6 above.

Equivalents are Belgium 743,014 (Farmdoc 43,126R) and Netherlands 69/18611.

(10) Cibas South Africa 69/ 8399 discloses compounds having the structure R as in 6 above.

An equivalent is Netherlands 68/ 18868. (Farmdoc 38,504).

(12) Cibas Netherlands 68/ 18868 (Farmdoc 38,505) discloses compounds having the structure R as in 6 above.

Equivalents are South Africa 8120/68, German 1,817,- 121 and Belgium 726,316.

(13) Fujisawas Great Britain 1,187,323, for example, at page 5, lines 67-71 discloses compounds having the structure 67/ 14888 (Farmdoc wherein R is as 13 above.

CH1 0 0H 6 Equivalents are Netherlands 68/06129 and South African 2695/68.

(15) Glaxos US. 3,243,435 and Belgium 650,444 (Farmdoc 15,535) disclose generally a vast variety of compounds having the structure OOH wherein R is defined, e.g. in columns 1 and 4, to include various heterocyclic groups.

(16) Cibas South Africa 65/6950 (Farmdoc 22, 192) discloses compounds having the structure OOH in which R in Example 20 is phenyl.

Equivalents are Great Britain 1,109,525 and Canada 807,651.

(17) Glaxos US. 3,479,350 discloses a process for producing S- yridiniummethyl cephalosporins which utilizes as an intermediate compounds of the type described in references 2 and 3 above.

SUMMARY OF THE INVENTION This invention comprises the compounds of the formula Ar-oH-ii-NH-on-oH-orr on, N=N

(50 O R (I) OH:

wherein Ar is phenyl, 2-thienyl or 3-thienyl and having the D configuration in the 7-sidechain and existing primarily as the zwitterion when R is hydrogen; wherein R is hydrogen, pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl or phenacyl; and their nontoxic, pharmaceutically acceptable salts.

Such salts include the nontoxic carboxylic acid salts thereof when R is hydrogen, including nontoxic metallic salts such as sodium, potassium, calcium and aluminum, the ammonium salt and substituted ammonium salts, e.g. salts of such nontoxic amines as trialkylamines, including triethylamine, procaine, dibenzylamine, N-benzyl-betaphenethylamine, l-ephenamine, N,N'-dibenzylethylenediamine, dehydroabietylamine, N,N'-bi.s-dehydroabietylethylenediamine, N-(lower)-alkylpiperidine, e.g., N-ethylpiperidine, and other amines which have been used to form salts with benzylpenicillin; and in all cases the nontoxic acid addition salts thereof (i.e., the amine salts) including the mineral acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, sulfate, sulfamate and phosphate and the organic acid addition salts such as the maleate, acetate, citrate, oxalate, succinate, benzoate, tartrate, fumarate, malate, mandelate, ascorbate and the like.

The compounds of the present invention are prepared according to the present invention by coupling with 7- amino-3-[S-(1 methyl-1,2,3-triazol 4 yl)carbonyl]- thiomethyl-3-cephem-4-carboxylic acid (II) (or a salt or easily hydrolyzed ester thereof including those of US. Patent 3,284,451 and UK. 1,229,453 and any of the silyl esters described in US. Patent 3,249,622 for use with 7- aminopenicillanic acid and used in Great Britain 1,073,- 530) a particular acid or its functional equivalent as an acylating agent for a primary amino group. After coupling, the blocking group is removed to give the desired product. Said acid has the formula Ar-CH-COOH NHB wherein Ar represents phenyl, 2-thienyl or 3-thienyl and wherein B represents a blocking group of the type used either in peptide syntheses or in any of the numerous syntheses of waminobenzylpenicillin from 2-phenylglycine. Particularly valuable blocking groups are a proton, as in the compound of the formula or a ,3-diketone as in Great Britain 1,123,333, e.g., methyl acetoacetate, in which case the acid containing the blocked amino group is preferably converted to a mixed anhydride, as with ethyl chloroformate, before reaction with Compound II or a salt thereof to form the desired product I after acid cleavage.

Further to the discussion above of blocking groups used on the free group of the sidechain acid during its coupling with Compound H, the blocking group is then removed to form the products of the present invention, e.g., the tbutoxy-carbonyl group is removed by treatment with formic acid, the carbobenxyloxy group is removed by catalytic hydrogenation, the Z-hydroxy-l-naphthcarbonyl group is removed by acid hydrolysis and the trichloroethoxycarbonyl group by treatment with zinc dust in glacial acetic acid. Obviously, other functionally equivalent blocking groups for an amino group can be used and such groups are considered within the scope of this invention.

Thus, with respect to said acid to be used to couple with Compound 11, functional equivalents include the corresponding acid anhydrides, including mixed anhydrides and particularly the mixed anhydrides prepared from stronger acids such as the lower aliphatic monoesters of carbonic acid, or alkyl and aryl sulfonic acids and of more hindered acids such as diphenylacetic acid. In addition, an acid azide or an active ester or thioester (e.g., with p-nitrophenol, 2,4-dinitrophenol, thiophenol, thioacetic acid) may be used or the free acid itself may be coupled with Compound II after first reacting said free acid with N,N'-dimethylchloroformiminium chloride [cf. Great Britain 1,008, 170 and Novak and Weichet, Experientia XXI, 6 360, (1965)] or by the use of enzymes or of an N,N'-carbonyldiimidazole or an N,N'-carbonylditriazole [cf. South African patent specification 63/ 2684] or a carbodiimide reagent [especially N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide or N- cyclohexyl N -(2- morpholinoethyl)carbodiimide; cf. Sheehan and Hess, J. Amer. Chem. Soc., 77, 1067 (1955)], or of alkylylamine reagent [cf. R. Buijle and H. G. Viche, Angew, Chem. International Edition 3, 582 (1964)], or of a ketenimine reagent [cf. C. L. Stevens and M. E. Mond, J. Amer. Chem. Soc., 80, (4065)] or of an isoxazolium salt reagent [cf. R. B. Woodwar, R. A. Olofson and H. Mayer, J. Amer. Chem. Soc., 83, 1010 (1961)]. Another equivalent of the acid chloride is a corresponding azolide, i.e., an amide of the corresponding acid whose amide nitrogen is a member of a quasiaromatic five-membered ring containing at least two nitrogen atoms, i.e., imidazole, pyrazole, the triazoles, benzimidazole, benzotriazole and their substituted derivatives. As an example of the general method for the preparation of an azolide, N,N'-carbonyldiimidazole is reacted with a carboxylic acid in equirnolar proportions at room temperature in tetrahydrofuran, chloroform, dimethylformamide or a similar inert solvent to form the carboxylic acid imidazolide in practically quantitative yield with liberation of carbon dioxide and one mole of imidazole. Dicarboxylic acids yield diimidazolide. The by-product, imidazole, precipitates and may be separated and the imidazolide isolated, but this is not essential. The methods for carrying out these reactions to produce a cephalosporin and the methods used to isolate the cephalosporin so produced are well known in the art.

In the treatment of bacterial infections in man, the compounds of this invention are administered orally or parenterally, in accordance with conventional procedures for antibiotic administration, in an amount of from about 5 to 200 mg./kg./ day and preferably about 5 to 20 mg./ kg./day in divided dosage, e.g., three to four times a day. They are administered in dosage units containing, for example, 125 or 250 or 500 mg. of active ingredient with suitable physiologically acceptable carriers or excipients. The dosage units are in the form of liquid preparations such as solutions or suspensions or as solids in tablets or capsules.

The preferred esters of the cephalosporins of the present invention are the pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl and phenacyl esters. All are useful intermediates in the production of the cephalosporin having a free carboxyl group and the first three are also of interest because on oral administration they provide different rates and amounts of absorption and give difiiering concentrations of the active antibacterial agent in blood and tissues.

As indicated above, these five esters of 7-aminocephalosporanic acid are each prepared by known methods. One excellent procedure is that of US. Pat. No. 3,284,451 in which sodium cephalothin is esterified by reaction with the corresponding active chloro or bromo compound (e.g. phenacyl bromide, chloroacetone, chloromethyl ether, pivaloyloxymethyl chloride [also called chloromethyl pivalate], acetoxymethyl chloride) and then the thionylacetic acid sidechain is removed enzymatically as in the same patent or chemically as in US. Pat. No. 3,575,970 and in Journal of Antibiotics, XXIV (11), 767-773 (1971). In another good method the triethylamine salt of 7-aminocephalosporanic acid is reacted directly with the active halogen compound, as in UK. 1,229,453.

These esters of 7-aminocephalosporanic acid are then reacted with the nucleophile in the same manner as is illustrated herein for 7-aminocephalosporanic acid itself. The 3-thiolated ester of 7-aminocephalosporanic acid is then coupled with the 2-arylglycine, e.g. D-()-2-phenylglycine, as before. Before or after removal of any blocking group on the a-amino group of the 2-arylglycine sidechain, the ester of the cephalosporin so obtained is, if not used per se, converted to its free acid, including its zwitterion (and, if desired, any salt) by removal of the esterifying group, as by aqueous or enzymatic hydrolysis (as with human or animal serum) or acidic or alkaline hydrolysis or by treatment with sodium triophenoxide as taught in US. 3,284,451 and, in the penicillin series, by Sheehan et al., J. Org. Chem. 29(7), 2006-2008 (1964).

In another alternative synthesis, the 3-thiolated 7-aminocephalosporanic acid is prepared as described herein and then acylated at the 7-amino group and finally esterified, as by reaction of the appropriate alcohol with the acid chloride prepared, for example, by reaction of the final cephalosporin with thionyl chloride or by other essentially acidic esterification procedures.

The preferred and most active compounds of the present invention are those having the D configuration at the a-carbon atom in the 7-sidechain, that is, those made from D-()-2-phenylglycine, which is also called D-(-)-aaminophenylacetic acid, and D-(-)-2-thienylg1ycine and D-()-3-thienylglycine. In addition, the configuration at the two optically active, asymmetric centers in the fi-lactam nucleus is that found in Cephalosporin C produced by fermentation and in the 7-aminocephalosporanic acid derived therefrom.

Potassium l-methyl-1,2,3,-triazole-4r-thiocarboxylate (A) 1-methyl-4-carboxyl-1,2,3-triazole.This product was prepared by the procedure of Christian Pedersen. Acta Chimica Scand. 13, 888 (1959).

A mixture of 78 g. (1.2 mole) NaN g. (0.8 mole) dimethylsulphate and 10 cc. of 50%NaOH in 200 cc. water was heated gently on a steam bath for ca. 45 min. (initially a vigorous gas evolution took place) in a distillation apparatus fitted in such a way as to collect the distillate (OH N +water) in 100 cc. of ice-cooled toluene. The CH N solution was dried over CaCl 200 cc. of dry benzene added and the resulting solution added to a cooled solution of 32 g. (0.45 mole) propiolic acid in 500 cc. toluene. The solution was allowed to stand at 22 C. for 48 hours. The crystalline product 1-meth'yl-4-carboxyl- 1,2,3-triazole was collected by filtration, washed with benzene and dried in vacuo. Yield 49.5 g. (87%) Ml. 205 dec. (theory 224 C.).

(Note: 1) The product could be recrystallized from water to M.P. 218-219".

(Note: 2) The product may contain up to 10% of another isomer (NMR).

(Note: 3) Using more concentrated solutions may lead to an exothermic reaction and loss of some CH N (B) l-methyl-1,2,3-triazole-4-carbonyl chloride.20.32 g. (0.16 mole) of the above acid with 5 drops dimethylformamide were heated under reflux in 200 cc. benzene. 40.8 g. (0.32 mole) (27.2 cc.) of oxalyl chloride in 50 cc. of benzene were added dropwise with stirring. After the addition, the solution was refluxed 2 hours, cooled and evaporated in vacuo. The residue was crystallized by dissolving in 95 cc. of benzene, and then diluting with 145 cc. of cyclohexane. Yield of 1-methy1-l,2,3-triazole- 4-carbonyl chloride 20.83 g. (89%), M.P. 106-108 C.

(C) l-methyl-1,2,3-triazole-4-thiocarboxylic acid (ptassi-um sa1t).20.83 g. (.143 mole) of the above acid chloride Was added portionwise with stirring and cooling at C. under N to an H 8 (phenophthalein end point) saturated solution of 4.2 g. (.286 mole) potassium metal in 250 cc. of absolute ethanol. The mixture was stirred 3 hours at 5 C., evaporated at 25 C. in vacuo (12 mm.) to yield 37.31 g. of product containing ca. 60% w./w. (95%) =1-methy1-1,2,3-triazole-4-thiocarboxylic acid (potassium salt). The main impurity was KCl.

7-amino-3- l-methyl-1,2,3-triazol-4-yl) carbonylthiomethyl-3-cephem-4-carboxylic acid To a stirred slurry of 27.2 g. (0.1 mole) of 7-aminocephalosporanic acid and 8.4 g. (0.1 mole) of sodium bicarbonate in 600 ml. of aqueous phosphate buttered at pH 6.4 was added 30.2 g. of potassium 1-methyl-1,2,3- triazole- 4 -thiocarboxylate (estimated purity 60% by weight). The mixture was heated under a nitrogen atmosphere for 5 hr. at 50, and was then stirred for 12 hr. with no external heating. The product was collected by filtration, washed with water and acetone and dried in vacuo over phosphorus pentoxide to yield 12.2 g. (34%) of 7-amino-3-(1-methyl 1,2,3 triazol-4-yl)carbonylthiomethyl-3-cephem-4-carboxylic acid as a crystalline solid, M.P. 233-235 dec. Infrared and NMR spectra were consistent with the structure.

Analysis.-Calcd. for C H N 0 S (percent): C, 40.57; H, 3.69; N, 19.71. Found (percent): C, 40.65; H, 3.83; N, 19.46.

The filtrate was adjusted to pH 6.4 with 6 N hydrochloric acid to provide a second crop of 5.9 g.

Pivaloyloxymethyl 7 -amino-3- l-methyl- 1,2, 3 -triazol-4- yl)-carbonylthiomethyl-3-cephem-4-carboxylate Method A.The title compound is produced by substituting for the 7-aminocephalosporanic acid used immediately above an equimolar weight of pivaloyloxymethyl 7 aminocephalosporanate hydrochloride prepared according to Example 2 of U.K. 1,229,453 from 7-aminocephalosporanic acid. German 1,904,585 (Farmdoc 39,445) is equivalent to U.K. 1,229,453.

Method B.-- The title compound is produced by substituting for the 0.025 mole (6.8 g.) 7-aminocephalosporanic acid used in the procedure of Example 2 of U.K. 1,229,453 an equimolar weight of 7-amino-3-(1-methyl- 1,2,3-triazol-4-yl)carbonylthiomethyl 3 cephem-4-carboxylic acid.

The respective acetoxymethyl, methoxymethyl, acetonyl and phenacyl esters of 7-amino-3-(l-methyl-1,2,3,-triazo1- 4-yl)-carbonylthiomethyl-3-cephem-4-carboxylic acid are prepared by substituting in Method B above for the chloromethyl pivalate used therein an equimolar weight of chloromethyl acetate, chloromethyl methyl ether, chloroacetone and phenacyl bromide, respectively.

Acetoxymethyl 7-amino-3-( 1methyl-1,2,3-triazol-4-yl)- carbonylthiomcthyl-S-cephem-4-carboxylate The title compound is produced by substituting for the 7-aminocephalosporanic acid used above (in the reaction with potassium 1-methyl-1,2,3-triazole-4-thiocarboxylate) an equimolar weight of acetoxymethyl 7-aminocephalosporanate hydrochloride prepared according to Binderup et al., Journal of Antibiotics, XXlV (11), 767-773 (November 1971).

In similar fashion the respective pivaloyloxymethyl, methoxymethyl, acetonyl and phenacyl esters of 7-aminocephalosporanic acid are prepared (as hydrochlorides) by replacing the chloromethyl acetate in the procedure of Binderup et al., ibid, with equimolar weights of chloromethyl pivalate, chloromethyl methyl ether, chloroacetone and phenacyl bromide, respectively. Each of these hydrochloride esters of 7-ACA is then reacted as was the 'acetoxymethyl ester hydrochloride to produce the corresponding ester of 7-amino-3-(1-methyl-l,2,3-triazol-4-yl) carbonylthiomethyl-3-cephem-4-carboxylic acid.

The following examples are given in illustration of, but not in limitation of, the present invention. All temperatures are given in degrees centigrade. 7-aminocephalosporanic acid is abbreviated as 7-ACA and methyl isobutyl ketone as MIBK. Skellysolve B is a petroleum ether fraction of BR 6068" C. consisting essentially of n-hexane.

DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLE 1 To a stirred slurry of 7.11 g. (.02 mole) of 7-amino- 3-(1-methyl 1,2,3 triazol-4-y1)carbonylthiomethyl-3- cephem-4-carboxylic acid in 200 ml. of dry methylene chloride were added successively 3.64 g. (.036 mole) of triethylamine, 5.32 g. (.044 mole) of N,N-dimethy1aniline and 6.54 g. (.06) mole of trimethylchlorosilane. The mixture was heated under reflux for 30 min. and was then cooled to 4. D(-)-2-phenylglycyl chloride hydrochloride (4.12 g., .02 mole) was added and the slurry was stirred for 1 hr. at 4-6 and then for 1 hr. without external cooling. The mixture was added to ml. of water with stirring and the material which precipitated was removed by filtration. The aqueous phase of the filtrate was layered with ethyl acetate and the pH adjusted to 4.5 by addition of 2 N sodium hydroxide. The solid which precipitated was collected by filtration, washed with water and with acetone and was dried in vacuo over phosphorus pentoxide to provide 3.24 g. of 7-[D-u-aminophenylacetamido] 3 (l-methyl-1,2,3-triazol-4-yl)-carbonylthiomethyl-3-cephem-4-carboxylic acid as a white amorphous solid, M.P. 168-170" dec. Infrared spectrum (KBr disc) showed absorption maxima (cmat 1780 (B-lactam carbonyl); 1700 (amide carbonyl); 1660 (thiolester carbonyl); 1610 and 1400 (carboxylate); 705 (phenyl). The NMR spectrum of a solution of this product in d -dimethylsulfoxide: deuterium oxide (1:2) and deuterium chloride (trace) showed absorptions [p.p.m. (a) from tetramethylsilane] which were assigned as follows: singlet (1H) at 8.55 due to the triazole ring proton; singlet (5H) at 7.53 due to the benzene ring protons; doublets centered at 5.75 (1H) and 5.11 (1H) for the p-lactam protons; multiplet (5H) from 4.49 to 3.85 for the exocyclic methylene and N-methyl protons; AB pattern (2H) centered at 3.50 for the protons at C of the dihydrothiazine ring.

acetyl chloride hydrochloride in the procedure of Example 1 for the D-(-) oz amino or phenylacetyl chloride hydrochloride used therein.

EXAMPLE 4 7 [D a amino cc (2 thienyD-acetamido] 3 (1- methyl 1,2,3 triazol 4 yl)carbonylthion1ethyl-3- cephem-4-carboxylic acid Following the exact same procedure as in Example 1 except using an equimolar weight of D-()-u-amino-a- (Z-thienyl)-acetylchloride hydrochloride in place of the D-()-2-phenylglycyl chloride hydrochloride used therein gives this compound.

TABLE 1 M.I.C. in meg/ml.

Organism New compound Cephalexin D. pneumoniae plus 5% serum A9585 5. 005- 0.16; 0.16 Str. Pyogenes plus 5% serum A9604 5. 0.16; 0.16 S. aureus Smith 1 A9537 0.3; 0.6; 1.3; 1.3. S. aureus Smith 1 plus 50% serum- A9537 4; 4; 2.5; 2.5; 1.3. S. aureus BX1633-2 at 10' dilution. A9606 1.3; 1.3; 1.3 2: 4: 2. S. aureus BX1633-2 at 10 dilution--- A9606 1; 2.5; 2.5 4; 4; 4. S. aureus meth.-resist.; at 10- dilution-.. A15097 4; 4; 2; 32; 32. S. aureus at 10 dilution--- A97 4; 4; 2; 32; 32. S. aureus at 10- dilution 8; 8; 63; 63. Sal. enteritidis 9 50. 4; 2. E. coli Juhl I 5 8; 8. E coli 2 4; 6; 32; 32. K. pneumoniae 5 4. K. pneumoniae I 2; 6; 16.- Pr. mirabilz's 5 4. Pnmorganii 32; 63,32 125;25 125, Pr. aeruainosa I A9843A 125; 125; 125--- $125; Sen'marceacem" A20019 125; 125; as 1 2 $125;

1 Nutrient Broth-45% Antibiotic Assay Broth. I At 10- dilution.

Blood levels in the mouse after oral administration were determined with the following results:

. n coNnj-r CHzR 4} Blood level in meg,/ml, after- OOH Dose. R= mgm,lkg, 1 0,5 1 1 1 2 1 3,5

0 NzN 100 7.9 13.2 6.8 1.3 II a 100 8.6 11.8 6.2 1.3 -s-o- N-CH,

H 100 30.5 16.6 5.0 1.1 (cephalexin)-monohydrate 100 34.4 22.4 4.8 0.7

1 Hours after administration,

EXAMPLE 2 EXAMPLE 5 Sodium 7 [D amino oz phenylacetamido) 3 [S- Acetox ymethyl 7 1 [D a am1nophenylacetam1do]-3- (1 methyl triazol 4 yncarbonynthlometh' (1 methyl 1,2,3 triazol 4 yl)-carbonylthiometh- 'cephem4'carbMy ate yl-3-cephem-4-carboxylate To a stirred aqueous suspension of the zwitterionic form of 7-[D-(u-arnino a phenylacetamido)-3-[S-(1- To a solutlon of acetoxymefliyl -(1- y methyl 1,2,3 triazol 4 yl)carbonyl] thiornethyl-3- 1,2,3 trlaZOl 4 YDCHTbOIIYIthIOmethYI 3 9 1 cephem-4-carboxylic acid (0.8 mole) is added 1 N aquecarbqxylafl? (regenerated from mole Of Its y ous sodium hydroxide at room temperature until a clear f i 1n l y acetate added 0.020 mole solution (pH 10.8) is obtained. This solution is impyrldlfle- The Xture 1S cooled 1n Ice and stirred wh1le mediately freeze-dried to give impure, solid sodium 7- mole -p yi y chlol'lde hydrochlo- [D (a amino a phenylacetamido) 3 5..(1 1 r1de in 30 ml. ethyl acetate 1s added over ten minutes. 1,2,3 triazol 4 yl)-carbonyl]thiomethyl-3-cephem-4- f' a further lfWfilltY mmutes in the cold, Stirring is carboxylate. continued at room temperature for one hour. Then the E AM 3 mixture is washed successively with aqueous sodium bicarbonate, 0.1 N hydrochloric acid and water, dried h amzmo g i g g and evaporated in vacuo to leave the desired acetoxymethy tlfiazo y )car lomet methyl 7-[D-a-aminophenylacetamido] 3 (l-methyl. cep em- -car oxy 0 am ,3 triazol 4 yl)-carbonylthiomethyl 3 cephem- This compound is prepared by substituting an equi- 4-carboxylate as an oil which crystallizes on trituration in molar weight of D-(--) 0c amino on (3 thienyl)- cyclohexane.

The respective pivaloyloxymethyl, methoxymethyl, acetonyl and phenacyl esters corresponding to the above acetoxymethyl ester are produced by replacing the acetoxymethyl 7-amino 3 (l-methyl 1,2,3 triazol-4- yl)carbonylthiomethyl 3 cephem 4 carboxylate hydrochloride used in the above procedure with 0.009 mole of the hydrochloride of pivaloyloxymethyl, methoxymethyl, acetonyl and phenacyl esters of 7-amino-3- (l-methyl 1,2,3 triazol 4 yl)-carbonylthiomethyl-3- cephem-4-carboxylic acid, respectively.

We claim:

1. A compound having the D configuration in the 7- sidechain and the formula 0 S Ar-CH-PJ-NH-CH-O OH, 0 N=N 1 111, d-cn,--s-

boon

wherein Ar is phenyl, 2-thienyl or 3-thienyl.

3. The sodium salt of a compound of claim 2. 4. The potassium salt of a compound of claim 2. 5. The zwitterion form of a compound of claim 2. 6. A nontoxic, pharmaceutically acceptable acid addition salt of a compound of claim 2.

7. The pivaloyloxymethyl ester of an acid of claim 2. 8. The acetoxymethyl ester of an acid of claim 2. 9. The methoxymethyl ester of an acid of claim 2. 10. The acetonyl ester of an acid of claim 2. 11. The phenacyl ester of an acid of claim 2. 12. A compound of claim 1 having the D configuration in the 7-sidechain and the formula wherein R is hydrogen, pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl or phenacyl; or a nontoxic, pharmaceutically acceptable salt thereof.

13."Ihe acid of claim 2 having the D configuration in the 7-sidechain and the formula 14. The sodium salt of the compound of claim 13.

15. The potassium salt of the compound of claim 13.

16. The zwitterion form of the compound ofclaim 13.

17. A nontoxic, pharmaceutically acceptable acid addition salt of the compound of claim 13.

18. The pivaloyloxymethyl ester of the acid of claim 13.

19. The acetoxymethyl ester of the acid of claim 13.

20. The methoxymethyl ester of the acid of claim 13.

21. The acetonyl ester of the acid of claim 13.

22. The phenacyl ester of the acid of claim 13.

wherein R is hydrogen, pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl or phenacyl; or a nontoxic, pharmaceutically acceptable salt thereof.

24. The acid of claim 2 having the D configuration in the 7-sidechain and the formula 25. The sodium salt of the compound of claim 24.

26. The potassium salt of the compound of claim 24.

27. The zwitterion form of the compound of claim 24.

28. A nontoxic, pharmaceutically acceptable acid addition salt of the compound of claim 24.

29. The pivaloyloxymethyl ester of the acid of claim 24.

30. The acetoxymethyl ester of the acid of claim 24.

31. The methoxymethyl ester of the acid of claim 24.

32. The acetonyl ester of the acid of claim 24.

33. The phenacyl ester of the acid of claim 24.

34. A compound of claim 1 having the D configuration in the 7-sidechain and the formula wherein R is hydrogen, pivaloyloxymethyl, acetoxymethyl, methoxymethyl, acetonyl or phenacyl; or a nontoxic, pharmaceutically acceptable salt thereof.

35. The acid of claim 2 having the D configuration in the 7-sidechain and the formula 36. The sodium salt of the compound of claim 35.

37. The potassium salt of the compound of claim 35.

38. The zwitterion form of the compound of claim 35.

39. A nontoxic, pharmaceutically acceptable acid addition salt of the compound of claim 35.

40. The pivaloyloxymethyl ester of the acid of claim 35. 41. The acetoxymethyl ester of the acid of claim 35.

42. The methoxymethyl ester of the acid of claim 35.

43. The acetonyl ester of the acid of claim 35.

44. The phenacyl ester of the acid of claim 35.

References Cited UNITED STATES PATENTS 3,641,012 2/1972 Ryan 260-443 C NICHOLAS S. RIZZO, Primary Examiner U.S. Cl. X.R. 424246 

